The acute respiratory distress syndrome is a significant cause of morbidity and mortality in critically ill patients. Angiopoietin-1 (Ang-1), a ligand for the endothelial Tie2 receptor, is an endothelial survival and vascular stabilization factor that reduces endothelial permeability and inhibits leukocyte-endothelium interactions. Objectives: We hypothesized that Ang-1 counteracts vascular inflammation and pulmonary vascular leak in experimental acute lung injury. Methods: We used cell-based gene therapy in a rat model of ALI. Transgenic mice overexpressing Ang-1 or deficient in the Tie2 receptor were also studied to better elucidate the mechanisms of protection.
100,000 population, and the mortality rate is estimated at 39% (2) . Indeed, ARDS was the principal feature in patients with severe acute respiratory syndrome (3, 4) , contributing substantially to morbidity and mortality, and emphasizing the need for new therapeutic strategies to effectively treat or prevent this pathology.
ARDS is characterized by influx of polymorphonuclear leukocytes in airspaces, and massive interstitial and alveolar accumulation of protein and fluid. Although the exact pathogenic mechanisms remain poorly defined, recent observations suggest that a disruption of normal endothelial function plays an important role (5) . Endothelial injury and subsequent loss of integrity of the endothelial barrier is a prerequisite for development of interstitial edema, and is associated with a marked increase in permeability in experimental models (6) (7) (8) (9) . In addition, endothelial activation and subsequent expression of molecules that mediate adhesion and signaling of leukocytes are required for the accumulation of inflammatory cells (10) (11) (12) . These insights into the mechanisms of injury and inflammation during ARDS have focused attention on therapeutic strategies targeting the pulmonary endothelium.
Angiopoietin (Ang)-1 is a ligand of the endothelial-selective tyrosine-kinase receptor, Tie2, and is an essential mediator of angiogenesis, promoting vessel maturation and stabilization (13) (14) (15) . Ang-1 is also an endothelial survival factor (16) , and was recently shown to protect blood vessels against plasma leakage in vivo and inhibit endothelial permeability in vitro (6, 17, 18) . Ang-1 inhibits leukocyte adhesion to vascular endothelium and reduces the expression of tissue factor and various adhesion molecules in endothelial cells stimulated by inflammatory cytokines (6, 19, 20) . These findings strongly support an antiinflammatory role for this proangiogenic and antiapoptotic factor, with the capacity to maintain endothelial function and prevent pathologic changes in endothelial gene expression. Consistent with this role, it was recently reported that neutrophil infiltration, capillary leakage, and lung edema in experimental acute lung injury (ALI) are associated with increased production of vascular endothelial growth factor (VEGF) and down-regulation of Ang-1 and Ang-4 (21) . In addition, pretreatment with an adenoviral construct encoding Ang-1 reduced mortality in mice with endotoxic shock (22) ; however, because transduction was limited to the liver in this experiment, it is not known whether the improved survival was due to systemic vascular effects of increased circulating levels of Ang-1 or to a direct effect on the lung, reducing vascular injury.
We hypothesized that local pulmonary gene transfer of Ang-1 would protect the lungs from LPS-induced ALI. Although gene therapy conceptually remains a promising treatment option for both genetically determined and idiopathic diseases, the use of viral vectors has been problematic, ranging from host immune responses to tumorigenesis. For this reason, we used cell-based gene therapy in a rat model of ALI to achieve targeted overexpression of Ang-1 in the lung microvasculature while circumventing the problems of in vivo transfection and avoiding the confounding effects of viral proteins (23) (24) (25) . Moreover, transgenic mice overexpressing Ang-1 or deficient in the Tie2 receptor were also studied to better elucidate the mechanisms of protection. We now report that Ang-1 overexpression reduced airspace inflammation and intraalveolar septal thickening after LPSinduced lung injury, associated with reduced expression of endothelial-selective adhesion molecules, and normalization of endothelial nitric oxide synthase (eNOS) and endothelin (ET)-1 expression. In contrast, deficiency in the Tie2 receptor resulted in increased susceptibility to lung injury and reduced survival after LPS exposure. These results have been previously reported in part in abstract form and in a conference proceeding (26) (27) (28) (29) .
METHODS

Cell Transfection
Skin fibroblast cells were isolated from syngeneic male Fisher344 rats (Charles River Co., Saint Constant, PQ, Canada) and transfected with null plasmid vector, pFLAG-CMV-1 (pFLAG), or the same vector containing the full-length cDNA for human Ang-1 (pAng-1) using Superfect (Qiagen, Valencia, CA), as previously described (23) (24) (25) . After 24 hours, cells were suspended in Dulbecco's phosphate-buffered Total Ang-1  5Ј-GAGCTCCTTGAGAATTACCTTGTGG-3Ј  5Ј-CGAGTTGATTTAGTACCTGGGTCTC-3Ј  Human Ang-1  5Ј-CTCCAATACTCACCCTGTTATGTC-3Ј  5Ј-GACACTGGAACAGTGTGAATCTGG-3Ј  Tie2  5Ј-AGAACAACATAGGATCAAGCAACCC-3Ј  5Ј-CTCTTCAGTTGCAACATAATCAGAAACG-3Ј  Rat ICAM-1  5Ј-CAGTGCTGTACCATGATCAGAATAC-3  5Ј-GTAATAGGTGTAAATGGACACCAC-3Ј  Rat VCAM-1  5Ј-ACGAGTGTGAATCGAAAACCGAAG-3Ј  5Ј-GTATTACCAAGGAGGATGCAAAGTAG-3Ј  Rat E-selectin  5Ј-GTGAGTATTCACCCTCTAATAGATG-3Ј  5Ј-CTCTCTAGAACTTGTGAACCAGAAC-3Ј  Rat P-selectin  5Ј-AGTCTTCACGAACGCTGCATATGAC-3Ј  5Ј-GACCAGGAAACTTGTTATCTGCATG-3Ј  Rat iNOS  5Ј-GAGACGTTCGATGTTCGAAGCAAAC-3Ј  5Ј-GCTTTGTTGAGGTCTAGAGACTCTG-3Ј  Rat eNOS  5Ј-CTACGAAGAATGGAAGTGGTTCC-3Ј  5Ј-GTGCTGAGCTGACAGAGTCGTACC-3Ј  Rat HO-1  5Ј-GAAGAGGAGATAGAGCGAAACAAGC-3Ј  5Ј-CTCGTGGAGACGCTTTACGTAGTGC-3Ј  Rat ET-1  5Ј-GCTTCTACAGTTTCTTGTTCAGAC-3Ј  5Ј-GGATGCAAACGAAGACAGGTTAGG-3Ј  Rat Ang-2  5Ј-TTTGTCTCCCAGCTGACCAGTGG-3Ј  5Ј-GACAGGTAGAAGTGCTCATACAG-3Ј  Rat VEGF  5Ј-CATAGGAGAGATGAGCTTCCTGC-3Ј  5Ј-CTCTGAACAAGGCTCACAGTGATTTTC-3Ј  18S 5Ј-GACGATCAGATACCGTCGTAGTTC-3Ј 5Ј-GTTTCAGCTTTGCAACCATACTCC-3Ј
Definition of abbreviations: Ang ϭ angiopoietin; eNOS ϭ endothelial nitric oxide synthase; ET ϭ endothelin; HO ϭ heme oxygenase; ICAM ϭ intercellular adhesion molecule; iNOS ϭ inducible nitric oxide synthase; VCAM ϭ vascular cell adhesion molecule; VEGF ϭ vascular endothelial growth factor. saline (PBS; Invitrogen, Carlsbad, CA) for injection into the pulmonary circulation.
Rat Model of ALI
All animal studies were conducted under protocols approved by the animal care committee at St. Michael's Hospital and in accordance with Canadian Council of Animal Care guidelines. Male Fisher344 rats (250 Ϯ 30 g) were randomly assigned to one of four experimental groups (n ϭ 10 rats/group). Transfected fibroblasts (1.5 ϫ 10 6 cells in 1 ml) were injected into the left exterior jugular vein and, 24 h later, rats received intratracheal instillation of saline or LPS (from Escherichia coli 026:B6; 100 g/kg body weight; 1 mg/ml; Sigma, St. Louis, MO). At 6 hours after instillation, rats were tracheotomized and bronchoalveolar lavage (BAL) performed. Lavage total cells were counted using a hemocytometer, and differential was determined by hematoxylin and eosin (H&E) staining. Lung tissue was flash frozen and blood plasma isolated. In separate rats, lung tissue was harvested by paraformaldehyde inflation.
Mouse Model of ALI
Female Tie2 haploinsufficient and Ang-1-overexpressing transgenic mice (both in CD1 background, 30 Ϯ 3 g) were randomly assigned to naive or LPS-challenged groups (n ϭ 5 mice/group) (30) (31) (32) . Wildtype (WT) littermates were used as control animals. Mice received intratracheal instillation of LPS (from E. coli 055:B5, 800 g in 50 l; Sigma) and, after 6 h, BAL was performed and blood plasma isolated. The left lung was flash frozen and the right lung was digested for flow cytometry. In separate mice, lung tissue was harvested by paraformaldehyde inflation.
Flow Cytometry
The right lung was perfused with 10 ml heparinized saline and inflated with 1 ml of dispaseII (3.6 U/ml; Roche, Basel, Switzerland), followed by 1 ml of 1% low-temperature agarose. The chest cavity was packed with ice for 5 min. The lung was removed and incubated in 1 ml of dispaseII at room temperature for 45 min and then transferred to 7 ml of Dulbecco's modified Eagle medium with 100 U/ml DNaseI (Roche) and separated into single cells by passing through a 70-m cell strainer. The isolated cells were suspended in staining buffer (2% heat-inactivated fetal calf serum, 0.09% sodium azide in Dulbecco's PBS; Invitrogen) and blocked using purified rat anti-mouse Fc block (BD Pharmingen, San Jose, CA). Cells were stained with phycoerythrin-conjugated anti-CD31 (0.2 mg/ml) and one of the following biotin-conjugated antibodies: anti-E-selectin (0.5 mg/ml), anti-P-selectin (0.5 mg/ml), antiintercellular adhesion molecule (ICAM)-1 (0.5 mg/ml), or anti-vascular cell adhesion molecule (VCAM)-1 (0.5 mg/ml), with streptavidin-APC Cy7 as the secondary stain (0.2 mg/ml; BD Pharmingen). Isotype controls were used to determine background staining. Flow cytometry was performed using the Beckman Coulter Cytomics FC500 (Fullerton, CA).
Quantitative Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was extracted from lungs using TRIzol reagent (Invitrogen) and reverse transcribed (RT; Qiagen). Quantitative polymerase chain reaction (PCR) was performed using SYBR GreenI PCR Master Mix and the ABI PRISM 7900HT (Applied Biosystems Inc., Foster City, Immunoprecipitation and Western blot analysis demonstrate that both Tie2 protein and phosphorylated Tie2 protein were decreased after LPS exposure and partially restored by pretreatment with pAng-1-transfected cells. *Significant differences versus pFLAG-transfected fibroblast-injected rats challenged with saline (p Ͻ 0.05); # significant differences versus pFLAG-transfected fibroblast-injected rats challenged with LPS (p Ͻ 0.05); n ϭ 10/group. Scale bar ϭ 100 m.
CA). ⌬C T analysis was used to calculate expression in comparison to 18S RNA. Primers for genes of interest are listed in Table 1 .
ELISAs
Rat tumor necrosis factor (TNF)-␣, IL-1␤, and IL-6 ELISA kits and mouse TNF-␣, IL-1␤, IL-6, soluble ICAM-1, soluble VCAM-1, soluble Total protein in BALF was increased 73% after challenge and pretreatment with pFLAG-transfected cells, and tended to be reduced by pretreatment with pAng-1-transfected cells. (E ) Lung wet weight-to-body weight ratio was increased 20% after LPS challenge and pretreatment with pFLAG-transfected cells, and tended to be reduced by pretreatment with pAng-1-transfected cells. *Significant differences versus pFLAG-transfected fibroblast-injected rats challenged with saline (p Ͻ 0.05); # significant differences versus pFLAG-transfected fibroblast-injected rats challenged with LPS (p Ͻ 0.05); n ϭ 10/group. Scale bar ϭ 100 m.
E-selectin, and soluble P-selectin ELISA kits were used, following the manufacturer's instructions (R&D Systems, Minneapolis, MN). The ET-1 ELISA kit (ALPCO Diagnostics, Salem, NH) was used following the manufacturer's instructions on precipitated lavage fluid spun at 3,000 ϫ g for 20 minutes.
Western Blots
Western Blots were performed using the following primary antibodies: rabbit anti-Tie2 (1:500), goat anti-Ang-1 (1:5,000), mouse anti-␤-actin (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit antiTyr992-phospho-Tie2 (1:1000; Cell Signaling Technology); goat antirat E-selectin (1:1,000), mouse anti-rat ICAM-1 (1:500; R&D Systems); and mouse anti-rat VCAM-1 (1:1,000; BD Pharmingen). Commercially available anti-rat P-selectin antibodies did not work with our Western blot system. Tie2 was immunoprecipitated using rabbit anti-Tie2 antibody and membranes probed with mouse anti-phosphotyrosine (1:4,000; Upstate Biotechnology; Lake Placid, NY). Predetermined molecular mass standards were used as markers (Invitrogen).
Immunohistochemistry and Histopathology
In separate experiments, 1.5 ϫ 10 6 CMTMR (chloromethylbenzolaminotetramethylrhodamine)-labeled rat fibroblast cells were injected into naive rats, which were killed 15 minutes, 24 hours, or 48 hours later. Confocal immunohistochemistry was performed on 15-m lung cryosections stained with rabbit anti-von Willebrand factor (50 g/ml; Dako, Mississauga, ON, Canada) or mouse anti-human Ang-1 (25 g/ml; Alpha Diagnostic International, San Antonio, TX).
Mouse and rat lung samples were fixed in 4% paraformaldehyde, paraffin embedded, cut into 5-m sections, and stained with H&E. Intraalveolar septal thickness was quantified by measuring all septae along a crosshair placed on each image (approximately 50 septae per animal) using ImageJ software (National Institutes of Health, Bethesda, MD).
Statistical Analysis
Data are represented as means (Ϯ SEM). Differences between groups were assessed using analysis of variance (with post hoc comparisons using Student-Newman-Keuls test). A value of p Ͻ 0.05 was considered statistically significant.
RESULTS
Role of Ang-1 in a Rat Model of ALI
Immunofluorescent staining of the lung with von Willebrand factor (green) to label the endothelium is shown in Figure 1A , a and b. At 15 minutes after injection, CMTMR-labeled fibroblasts (red) were visible in or near small arterioles (a), persisting in the lungs 48 hours later (b). CMTMR-labeled fibroblasts were not detectable in liver, spleen, or kidney (data not shown), and have previously been shown to persist in the lung for up to 6 months (24) . Immunofluorescent staining of the lung for Ang-1 (green) is shown Figure 1A , c and d. The expression of the Ang-1 transgene by transplanted fibroblasts is evident by the yellow color, indicating colocalization of CMTMR and Ang-1 signals, 15 minutes after injection (c), again persisting for 48 hours after injection (d). Immunohistochemical staining confirmed that Ang-1-expressing fibroblasts persist in the lung even after LPS exposure (data not shown). Quantitative real-time RT-PCR analysis of total Ang-1 mRNA levels showed a reduction in total Ang-1 mRNA of 53% after LPS exposure compared with saline with pFLAG-transfected cells ( Figure 1B) . Pretreatment with pAng-1-transfected cells restored total Ang-1 mRNA to sham levels. In contrast, plasmid-derived Ang-1 mRNA was undetectable in animals pretreated with pFLAG-transfected cells, whereas plasmid Ang-1 transcript levels were similar in both groups that received injection of pAng-1-transfected cells ( Figure 1C) . RT-PCR analysis of the receptor tyrosine kinase, Tie2, demonstrated a reduction in Tie2 mRNA of 59% after LPS exposure compared with saline with pFLAG-transfected Definition of abbreviation: FB ϭ fibroblast. * p Ͻ 0.05 versus pFLAG-transfected fibroblast-injected rats challenged with saline.
† p Ͻ 0.05 versus pFLAG-transfected fibroblast-injected rats challenged with LPS.
cells ( Figure 1D) ; and, pretreatment with pAng-1-transfected cells partially restored Tie2 expression. Moreover, both total Tie2 and phosphorylated Tie2 protein were decreased after LPS exposure compared with saline with pFLAG-transfected cells ( Figure 1E ), which again was partially restored by pretreatment with pAng-1-transfected cells. Ang-1 cell therapy attenuated intraalveolar septal thickness and airspace inflammation in rats. Administration of pAng-1-transfected cells, compared with pFLAG-transfected cells, did not significantly alter lung morphology in rats that received intratracheal instillation of normal saline ( Figure 2A, a and b) . Intraalveolar septal thickness and total cell count in BAL fluid (BALF) were increased two-and fourfold, respectively, after LPS exposure compared with saline ( Figure 2A Figures 2B and 2C) . The reduction in total BALF cells was mainly attributable to a reduction in the number of neutrophils (Table 2) .
Total protein in BALF and lung wet weight-to-body weight ratio were increased after LPS exposure compared with saline ( Figures 2D and 2E ). There was a trend toward a reduction in these indicators of pulmonary vascular leak in animals receiving Ang-1 cell therapy (p ϭ 0.10 for BALF protein; p ϭ 0.09 for wet weight-to-body weight ratio).
Ang-1 cell therapy did not reduce expression of proinflammatory cytokines in rats. To further assess the effect of Ang-1 cell therapy on lung inflammation, proinflammatory cytokines were measured in BALF and plasma. Basal cytokine levels in lavage fluid were not different in control animals receiving pAng-1-or pFLAG-transfected cells (Table 3 ). Exposure to LPS increased levels of TNF-␣, IL-6, and IL-1␤ in lavage fluid by 30-, 22-, and 2-fold, respectively, and pretreatment with pAng-1-transfected cells failed to reduce elevated BALF cytokine levels in LPStreated animals. To assess systemic inflammation, plasma concentrations of these proinflammatory cytokines were measured; however, only IL-6 was detectable in plasma 6 hours after LPS exposure, and was not reduced with Ang-1 cell therapy. Selective effect of Ang-1 cell therapy on endothelial adhesion molecule expression in rats. In animals receiving pFLAGtransfected cells, mRNA levels for ICAM-1, VCAM-1, P-selectin, and E-selectin in whole lung tissue were increased by 2-to 32-fold after exposure to LPS compared with saline ( Figures 3A-3D) . The increases in ICAM-1, VCAM-1, and P-selectin mRNA levels after LPS were similar in rats receiving pAng-1-compared with pFLAG-transfected cells. In contrast, pretreatment with pAng-1-transfected cells largely prevented the increase in mRNA expression of the endothelial-selective adhesion molecule, E-selectin, in LPS-treated rats ( Figure 3C ). Western blot analysis showed no difference in ICAM-1 or VCAM-1 protein expression between the experimental groups, Western blot analysis of VCAM-1 showed no detectable difference in VCAM-1 expression between all experimental groups. (C ) Quantitative real-time RT-PCR analysis of total E-selectin mRNA levels shows a 22-fold increase after LPS that was significantly attenuated by pretreatment with pAng-1-transfected cells. Western blot analysis of E-selectin showed similar expression to mRNA levels. (D ) Quantitative real-time RT-PCR analysis of total P-selectin mRNA levels shows a 32-fold increase after LPS that was not affected by pretreatment with pAng-1-transfected cells. Western blot analysis of P-selectin was not performed due to lack of commercially available antibodies. *Significant differences versus pFLAGtransfected fibroblast-injected rats challenged with saline (p Ͻ 0.05); # significant differences versus pFLAG-transfected fibroblastinjected rats challenged with LPS (p Ͻ 0.05); n ϭ 10/group. whereas E-selectin protein was induced by LPS exposure, and this was substantially reduced by the administration of pAng-1-transfected cells.
Ang-1 cell therapy affects vasoactive gene expression in rats. In the control animals, the expression of heme oxygenase-1 (HO-1) mRNA in whole lung was significantly increased by pAng-1 gene transfer in the absence of LPS exposure (Table 4) , whereas Ang-1 alone had no effect on the expression of the other genes studied. LPS exposure produced a marked increase in the mRNA expression of inducible NOS (55-fold; p Ͻ 0.05) in the nulltransfected group, with more modest increases in mRNA levels of ET-1 (threefold; p Ͻ 0.05), HO-1 (twofold; p Ͻ 0.05) and Ang-2 (1.5-fold; p Ͻ 0.05). In LPS-treated animals, Ang-1 gene transfer reduced ET-1 and increased eNOS mRNA expression in the lung compared with null (pFLAG) gene transfer in LPS, but did not alter the expression of inducible NOS. ET-1 protein in BALF by ELISA was increased 5.6-fold after LPS compared with saline with pFLAG-transfected cells, and this was reduced 
Role of Ang-1 in Transgenic Models of ALI
Experiments were performed using Tie2 heterozygous-deficient mice (Tie2 ϩ/Ϫ ) or binary transgenic mice in which Dox-conditional Ang-1 overexpression was targeted to endothelium using the Tie1 promoter, tTA-Ang-1. WT littermates were used as control animals. Total lung Ang-1 protein expression by Western blot analysis was not different between endothelial-targeted, Ang-1-overexpressing mice and WT or Tie2 heterozygousdeficient mice ( Figure 4A ). This may be a result of high basal levels of pulmonary Ang-1 expression in extraendothelial cells under normal conditions (17, 18) , which may overshadow the human Ang-1 transgene expression, which is restricted to the endothelium. However, the decrease in Ang-1 protein expression seen in WT mice after LPS challenge was blunted in tTA-Ang-1 mice. Paradoxically, the LPS-induced reduction in Ang-1 was also attenuated in Tie2-deficient mice, which we hypothesize might reflect a compensatory mechanism for the very low expression of Tie2 in these animals. As expected, basal Tie2 expression was reduced by about 50% in Tie2 ϩ/Ϫ compared with WT mice (Figure 4B ), and Tie2 protein was markedly down-regulated by LPS exposure in WT mice, which was further reduced in Tie2 ϩ/Ϫ . Septal thickness and airspace inflammation in transgenic mice. In the absence of LPS, lung morphology was not significantly different between groups of transgenic mice ( Figure 5A ). The intraalveolar septal thickness increased 2.7-fold after LPS exposure in WT mice ( Figure 5B ). This increase in septal thickness was significantly blunted in Ang-1-overexpressing mice, whereas Tie2-deficient mice exhibited nearly a 50% greater increase in intraalveolar septal thickness in response to LPS compared with WT animals. LPS-induced airspace inflammation mirrored these differences with the increase in total cells in BALF. This increase, attributable mainly to an increase in neutrophils, was markedly blunted in Ang-1-overexpressing mice, whereas Tie2-deficient animals consistently exhibited exaggerated airspace inflammation ( Figure 5C ; Table 5 ). Total protein in BALF was increased threefold after LPS in WT mice, and again this was suppressed in Ang-1-overexpressing mice and increased in Tie2-deficient animals ( Figure 5D ). In addition, mortality was higher in Tie2-haploinsufficient mice subjected to LPS challenge (60% mortality within 1 h) compared with the other experimental groups (17%; p Ͻ 0.02). Necropsy revealed that mortality was associated with massive alveolar flooding in Tie2-deficient mice.
Proinflammatory cytokines in transgenic mice. TNF-␣, IL-1␤, and IL-6 were undetectable in control mice, and were all markedly increased in lavage fluid after LPS exposure in WT mice ( Figures 6A-6C) . In contrast to Ang-1 gene transfer in the rat, Ang-1-transgenic mice exhibited significant reductions in all three cytokines in response to LPS. Heterozygous Tie2-deficient animals exhibited similar increases in cytokine levels compared with WT mice, with the exception of IL-6, which was higher.
Ang-1 overexpression reduces endothelial expression of adhesion molecules. To evaluate changes in the expression of adhesion molecules in endothelial cells versus other lung cell types, mouse lungs were digested in dispase and stained for the endothelial cell marker, CD31. Subsequently, flow cytometry was performed for each adhesion molecule separately using two-color flow cytometry, gated around the CD31 ϩ and CD31 Ϫ populations. The percentage of endothelial cells positive for E-selectin, P-selectin, ICAM-1, and VCAM-1 increased from 4-to 34-fold after LPS in WT mice ( Figure 7A, left panels) . Endothelial-targeted Ang-1 overexpression nearly completely suppressed the LPS-induced increases in endothelial expression of E-selectin, P-selectin, and VCAM-1 ( Figures 7A, 7B , and 7D), but had only a marginal effect on ICAM-1 expression ( Figure 7C) . Surprisingly, Tie2-deficient mice showed similar, although more modest, reductions in adhesion molecule expression in response to LPS. This may be explained by greater adhesion molecule shedding in these animals (Figure 8 ), consistent with more advanced inflammation. In addition, similar changes, although with lower overall numbers of positive cells, were seen when the expression of these adhesion molecules was studied in all dispersed lung cells (Figure 7 , right panels).
DISCUSSION
We investigated the relevance of the Ang-1/Tie2 system in modulating lung vascular injury using both gene transfer and transgenic approaches. In both the rat and mouse models, Ang-1 overexpression markedly reduced septal edema in response to LPS, as well as alveolar and endothelial inflammation, whereas Tie2-haploinsufficient mice showed an exaggerated response and had significantly greater short-term mortality. These data underscore the protective role of this pathway in maintaining pulmonary vascular homeostasis, and support the potential utility of Ang-1 in the treatment of acute lung injury.
In addition to being an essential mediator of angiogenesis (13-15), Ang-1 is an important endothelial survival factor, and has been shown to inhibit apoptosis in cultured endothelial cells induced by serum starvation, irradiation, and mannitol (16, 33) . Ang-1 decreased vascular permeability in Ang-1-overexpressing mice (17) , and acute administration of Ang-1 protected against VEGF-induced vascular leak (18) . In a cell culture model, Ang-1 was shown to inhibit leukocyte migration across an endothelial monolayer, due to a reduction in endothelial expression of E-selectin, ICAM-1, and VCAM-1 (6, 19, 20) . Karmpaliotis and colleagues (21) observed that endogenous Ang-1 expression was decreased in response to LPS in a murine model of ALI, whereas VEGF was increased. Similarly, we found a dose-dependent decrease in E-selectin, VCAM-1, and ICAM-1 by RT-PCR analysis in TNF-␣-treated human dermal microvascular endothelial cells incubated with Ang-1 protein (data not shown), in agreement with previous reports (6, 33) .
The endothelial monolayer plays a critical role in many aspects of the pathogenesis of ALI and ARDS (5, 34-36). Alterations in the production of vasoactive mediators by injured endothelium leads to impaired hypoxic pulmonary vasoconstriction (37, 38) . Increased expression of angiogenic growth factors, such as VEGF, contributes to increased endothelial permeability and interstitial edema, increased pulmonary dead space, and vascular remodeling (6-9, 21, 39) . However, perhaps the most important role of the endothelium in ALI and ARDS is in regulation of inflammation (5, 10, 40, 41) . Leukocyte adhesion to the endothelium is a prerequisite for migration into the lung parenchyma, where the inflammatory cells contribute to lung injury (10) (11) (12) . Indeed, previous studies have reported attenuation of lung injury in experimental ALI by blocking endothelial adhesion molecules (42, 43) . Thus, strategies to selectively reduce endothelial inflammation in response to injury could be of potential benefit, not only in ALI and ARDS, but also in systemic inflammatory disorders, such as the systemic inflammatory response syndrome, sepsis, and the multiple organ dysfunction/ failure syndrome.
Ang-1 cell-based gene transfer also resulted in several downstream effects in the rat model of ALI. Expression of two protective enzymes, eNOS and HO-1, was increased after Ang-1 cell therapy in LPS-challenged rats. Mice overexpressing eNOS were previously shown to be protected from lung injury during endotoxic shock (44) . HO-1 is known to increase during ARDS (45) , and the increase in HO-1 activity is thought to be a protective mechanism (46) . In addition, ET-1, which was previously shown to increase inflammation and pulmonary-vascular leak in ARDS, was reduced after Ang-1 cell therapy compared with LPS-challenged control animals (47) . ET-1 receptor antagonists have been shown to be protective in an experimental model of ALI (48); thus, the mechanisms of protection of Ang-1 likely include modulation of the production of vasoactive factors.
The Tie2 receptor is expressed predominantly on endothelial cells, as well as on some hematopoietic and inflammatory cells; thus, Ang-1 therapy in the lung would mainly target the vascular endothelium (49) . It is likely, for this reason, that Ang-1 overexpression in the rat model only reduced the expression of adhesion molecules that are largely endothelial restricted, such as E-selectin, whereas no effect was seen for VCAM-1 and ICAM-1, which are also expressed on smooth muscle cells and type I and II epithelial cells.
The transgenic mouse models overcame some of the potential limitations of the gene transfer approach. Whereas cell-based gene transfer resulted in focal regions of Ang-1 overexpression, localized mainly to the precapillary arteriole, Ang-1-tTA mice expressed Ang-1 uniformly in the lung endothelium. This may explain why the protection seen against LPS-induced microvascular injury was more complete in the transgenic model. In addition, unlike the rat model, total lung P-selectin, ICAM-1, and VCAM-1, as well as E-selectin, were all reduced to varying degrees in the Ang-1-transgenic mouse after LPS exposure. Moreover, in this model, we were able to distinguish between endothelial and nonendothelial adhesion molecule expression by flow cytometric analysis after tissue dispersion. Endothelial expression of ICAM-1, VCAM-1, P-selectin, and E-selectin were attenuated in Ang-1-overexpressing mice compared with WT mice; there were no significant differences in nonendothelial adhesion molecule expression between the experimental groups.
In contrast, Tie2-deficient mice exhibited increased susceptibility to lung injury after LPS, with higher levels of inflammatory cells and protein in BALF, increased intraalveolar septal thickening, and higher early mortality than in WT mice. The only exception was the unexpected reduction in adhesion molecule expression in dispersed lung in Tie2-deficient mice compared with WT mice. However, these animals also exhibited increased circulating levels of soluble adhesion molecules, and it is possible that the lower cellular expression of adhesion molecules may reflect more extensive and rapid shedding from the endothelial cells, as well as other lung cell types, in the Tie2-haploinsufficient mice. It is important to note that circulating soluble adhesion molecule expression has been correlated with severity of ARDS, as well as mortality rates (19, 50, 51) . Soluble adhesion molecule expression may increase when adhesion molecules are shed or proteolytically cleaved after endothelial-leukocyte interaction, or by up-regulation of a soluble variant of these adhesion molecules (52) (53) (54) .
Ang-1 cell therapy represents a possible therapeutic strategy to prevent development of clinical ARDS (55) . Cell-based gene therapy could be advantageous over intravenous administration of recombinant Ang-1 protein, as it allows for more targeted expression of the transgene and overcomes issues of short protein half-life after injection. A number of clinical trials are currently underway assessing the safety and efficacy of cell therapy in several different pathologies. In addition, endothelial progenitor cells and mesenchymal stem cells may also provide protection above and beyond that provided by increased Ang-1 expression, as these cells may release many additional mediators that could be beneficial (56, 57) .
In this report, we demonstrate a strong protective role for the Ang-1/Tie2 system in experimental ALI. The benefits of Ang-1 overexpression were seen in two experimental models, showing reduced vascular endothelial inflammation and leakage. Overexpression of Ang-1 blunted endothelial adhesion molecule expression, increased HO-1 and eNOS expression, and decreased ET-1 expression, all of which likely contributed to reduced airspace inflammation, intraalveolar septal thickening, and early mortality. Therefore, these results suggest that Ang-1 therapy may represent a potential new treatment strategy to reduce the vascular consequences of lung injury, which are a major determinant of morbidity and mortality in critically ill patients.
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